SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results beat expectations and marked its first profitable quarter since its IPO, with AI and compute growth driving much of the excitement. Traders celebrated the earnings-fueled rally and potential short squeeze, while others questioned the valuation and heavy AI spending; preliminary Tesla merger discussions and an upcoming share unlock also drew attention.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares are under pressure after its quarterly profit beat expectations, but a softer fourth-quarter outlook and slowing revenue growth overshadowed the results; the company also lowered its advertising revenue forecast. Bears see growth and ad execution as key concerns, while bulls argue the selloff overstates the risk given the profitable quarter and share buybacks.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reported Chinese orders for Nvidias export-compliant GPUs are renewing discussion of strong AI-chip demand, though traders are frustrated that the news has not translated into a stronger share-price response. The debate also reflects optimism about continued AI infrastructure spending after SpaceX and Super Micro updates, balanced by worries about valuations, financing, and whether that spending will generate returns.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary fiscal Q1 update sharply raised its sales outlook and projected improved gross margins, citing stronger AI-platform demand. Bulls welcomed the upside surprise and speculated about short covering, while skeptics questioned whether the gains and improved margins would hold.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys upcoming Q3 earnings are the main focus, with traders debating whether results and guidance can justify its premium valuation after a sharp, volatile pullback. Bulls point to fuel-cell demand from AI data centers and recent power-project deals, while skeptics warn that expectations are high and the broader AI selloff could keep shares under pressure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS shares sharp rebound has traders focused on the anticipated 80th-event trigger and final analysis of its Phase 3 REGAL AML trial, with some also speculating about a buyout. The event count and trial results remain unconfirmed; bullish expectations of a major catalyst are countered by skepticism that the move is trading momentum without new data.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Traders are focused on potential DefenCath reimbursement upside after the HHS kidney-care plan highlighted barriers to financing dialysis innovation, which they see as support for CorMedixs request for a separate infection-prevention payment category. CMS action remains uncertain, and the discussion also weighs DefenCaths adoption and pricing against competition; REZZAYOs FDA priority review is another cited growth catalyst.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is being swept up in a semiconductor selloff as traders question the returns and financing behind AI infrastructure spending; Hock Tans casino remarks have added to skepticism. The community is split between dip-buyers pointing to continuing AI-chip demand and bearish traders focused on AVGOs weak performance, credit concerns, and the risk of further declines.

Tema ETF Trust - Tema Space Innovators ETF

Tema Space Innovators ETF

SpaceXs AI-driven revenue growth and first quarterly profit have drawn attention to NASAs sizable SpaceX exposure, but traders note the ETF is falling despite SpaceXs after-hours strength. The discussion is split between investors viewing the pullback and fresh lows as an accumulation opportunity and holders frustrated by the funds weakness and broader space-sector underperformance.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Traders are focused on Seas reported plans for a Monee fintech listing and a new AI cloud business, with the announcements coinciding with a sharp selloff. The community is split between seeing the moves as potential value creation and worrying about uncertainty, spending, and Shopee competition; some also view the decline as an oversold buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB...

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.

CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus

Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.

Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?

Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026...

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

AnaptysBio Inc

ANAB Stock Falls After Company Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Anaptys alleges that Tesaro violated the terms of the 2014 deal between the two companies.&nbsp;</li><li>The company said that it approached Tesaro to resolve the claims, but Tesaro initiated a lawsuit against it.</li><li>A trial is now anticipated in July 2026, and milestone and royalty payments continue to be due to Anaptys during the proceedings.</li></ul><p>AnaptysBio, Inc. (ANAB) said on Friday that it has initiated litigation against GSK unit Tesaro, alleging a breach of the terms of the collaboration agreement between the two companies, inked in March 2014. This renewed battle adds to a fraught relationship between the two companies, with a trial now expected in July next year.</p><p><a href="https://stocktwits.com/symbol/ANAB">ANAB shares</a> dipped 10% in the pre-market session at the time of writing.</p><h2 class="st-heading-2">New Legal Fight</h2><p>Anaptys has<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-initiates-litigation-against-tesaro-gsk-subsidiary"> requested</a> that the court declare that Anaptys is entitled to all rights and remedies under the collaboration agreement. The company alleged that Tesaro violated exclusivity obligations by participating in past, ongoing, and upcoming governed clinical trials with PD-1 antagonists, a type of immunotherapy, and failed to use commercially reasonable efforts to obtain optimum commercial return for its immunotherapy called Jemperli. A trial is now anticipated in July 2026 and milestone and royalty payments continue to be due to Anaptys during the proceedings.</p><p>The company said that it approached Tesaro to resolve the claims, but Tesaro initiated a lawsuit against it. Tesaro, in turn, alleges that Anaptys breached the agreement between the two companies. Anaptys said that Tesaro’s claims are entirely without merit and that it intends to pursue all appropriate legal remedies against Tesaro.</p><h2 class="st-heading-2">Previous Litigation</h2><p>Anaptys filed a complaint previously against GSK in 2020, alleging that GSK’s planned trial of Zejula in combination with Merck’s Keytruda violated the exclusivity obligations under the 2014 deal.</p><p>The complaint resulted in a settlement that included a cash payment.</p><h2 class="st-heading-2">$100M Stock Repurchase Plan</h2><p>Separately, Anaptys also announced that its Board of Directors has authorized an amended stock repurchase plan under which the company may repurchase up to $100 million of the company’s outstanding common stock. This is in addition to the $6.4 million that remained as of Nov. 20, 2025, under the current $75 million stock repurchase plan.</p><p>The shares may be repurchased from time to time in open market transactions, and the stock repurchase plan will expire on March 31, 2026, the company said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around ANAB stayed within the ‘neutral’ territory over the past 24 hours while message volume stayed at ‘extremely low’ levels.</p><figure class="image"><img style="aspect-ratio:584/61;" src="data:image/png;base64,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" width="584" height="61" alt="ANAB’s Sentiment Meter and Message Volume as of 7:05 a.m. ET on Nov. 21, 2025 | Source: Stocktwits"><figcaption>ANAB’s Sentiment Meter and Message Volume as of 7:05 a.m. ET on Nov. 21, 2025 | Source: Stocktwits</figcaption></figure><p>ANAB stock has nearly tripled this year and gained 78% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/foxconn-to-pour-up-to-5b-into-us-plants-after-striking-servers-deal-with-openai/cLPMZruREOB">Foxconn To Pour Up To $5B Into US Plants After Striking Servers Deal With OpenAI</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen in Athens, Greece on January 13, 2023. (Photo illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

The dispute centers around Tesaro’s participation in PD-1 trials. 

Glaxosmithkline plc - ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$45.43
Prev Close	$49.24
Open	$49.57
Dividend Yield	0.00%
50-Day Moving Average	$53.23
Beta	0.87
Avg. Volume	596,211.65
PE Ratio	7.05

52-Week High	$72.36
52-Week Low	$20.18
Market Capitalization	$1.47B
EPS (Annual)	-$0.4601
Price to Book	127.59
Revenue Per Employee	$2.26M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANAB Fundamentals